02 Dec 09 Phosphagenics commences Phase 1B clinical trial of its oxycodone/TPM transdermal patch systems (News-Medical-Net)
Phosphagenics Limited today announced the initiation of a Phase 1B clinical trial for its patented oxycodone/TPM (Targeted Penetration Matrix) transdermal patch systems.
Read the original post:
Phosphagenics commences Phase 1B clinical trial of its oxycodone/TPM transdermal patch systems (News-Medical-Net)
Tags: clinical-trial, initiation, penetration, the-initiation, today-announced
02 Dec 09 First Subject Dosed in Phase 1B Clinical Trial of Phosphagenics’ Patented Oxycodone Patch (Business Wire via Yahoo! Finance)
MELBOURNE, Australia—-Phosphagenics Limited today announced the initiation of a Phase 1B clinical trial for its patented oxycodone/TPM transdermal patch systems.
Tags: initiation, the-initiation, today-announced
01 Dec 09 QRxPharma Initiates Pivotal Phase 3 Study Of MoxDuo(TM)IR For Moderate To Severe Acute Pain (Medical News Today)
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced, as part of its Phase 3 program, the initiation of a registration (also called pivotal) trial (Study 008) comparing efficacy and safety profiles of MoxDuo(TM)IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery. The Company expects to complete …
See the rest here:
QRxPharma Initiates Pivotal Phase 3 Study Of MoxDuo(TM)IR For Moderate To Severe Acute Pain (Medical News Today)
Tags: city-community, initiation, pain-following
30 Nov 09 QRxPharma commences Phase 3 pivotal trial of MoxDuo IR (News-Medical-Net)
QRxPharma Limited announced today, as part of its Phase 3 program, the initiation of a registration (also called pivotal) trial (Study 008) comparing efficacy and safety profiles of MoxDuo(TM)IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery. The Company expects to complete dosing by close of Q2 …
Here is the original:
QRxPharma commences Phase 3 pivotal trial of MoxDuo IR (News-Medical-Net)
Tags: complete-dosing, initiation, management, oxycodone-alone
24 Jul 09 QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study For MoxDuo(TM) IV Pain Therapy (Medical News Today)
QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced the initiation of a Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery.
Go here to read the rest:
QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study For MoxDuo(TM) IV Pain Therapy (Medical News Today)
Tags: efficacy, hip-replacement, initiation, morphine-alone, pharma-limited
